For millions of men suffering from benign prostatic hyperplasia, the options often boil down to ineffective drugs or invasive surgery. Zenflow, Inc., which offers a less traumatic alternative, has now secured a $52.0M Series d funding round.
The company's Spring System is designed to be deployed in a urologist's office, providing an atraumatic procedure for urinary obstruction that avoids the high risk of side effects like sexual dysfunction associated with traditional surgery. With ongoing clinical trials showing positive results out to four years, the latest capital infusion saw participation from Cook Medical, ClavystBio, Invus Opportunities, F-Prime, Medtech Venture Partners, HSBC Bank USA, N.A., and Trinity Capital.


















